Loading data for COGT — first visit, this takes a few seconds.
Cogent Biosciences, Inc. (COGT)
NasdaqGS: COGT
· 即時價格 · USD
33.41
-0.67 (-1.97%)
收盤價： Sep 11, 2026, 8:00 PM
33.33
-0.24%
盤後: 7:57 PM
股價、關鍵數字和最新消息，都在這一頁。
Cogent Biosciences, Inc.（COGT）股價、分析與資料
無可用資料
| 買價 | 25.1 |
| 市值 | 5.8B |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -377M |
| 0.31 | |
| -2.16 | |
| n/a | |
| -30.57 | |
| P/B (ttm) | 12.27 |
| P/S (ttm) | 0.00 |
| 財報日期 | Nov 3, 2026 |
| 賣價 | 42.9 |
| 成交量 | 1,715,775 |
| 20 日平均成交量 | 2,280,703 |
| 開盤價 | 34.51 |
| 前收盤價 | 34.08 |
| 當日區間 | 33.21 - 35.00 |
| 52 週範圍 | 11.60 - 43.73 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 COGT
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found...
完整的公司簡介財報驚奇
Cogent Biosciences 已於 Aug 10, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -0.52 超出預期 0.04, 年增 1.89% 成長.
第 1 頁，共 2 頁